Search research articles
Contact Us
Filters
Showing results (1-10 of 41) with videos related to
Page
of 5
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 26, 2004
The therapeutic value of cannabinoids in MS: real or imaginary?
Joep Killestein, Chris Polman
Lancet (London, England)
|
March 3, 2009
Improving function: a new treatment era for multiple sclerosis?
Alan Thompson, Chris Polman
Neurology
|
February 23, 2011
Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy
Reinhard Hohlfeld, Frederik Barkhof, Chris Polman
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
June 13, 2006
Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?
Chris Polman, Huub Schellekens, Joep Killestein
The Lancet. Neurology
|
December 29, 2004
Biological markers in CSF and blood for axonal degeneration in multiple sclerosis
Charlotte E Teunissen, Christine Dijkstra, Chris Polman
JAMA Neurology
|
November 7, 2012
Natalizumab: bench to bedside and beyond
Richard Rudick, Chris Polman, David Clifford, et al.
Neuroscience and Biobehavioral Reviews
|
September 7, 2005
Pain in Parkinson's disease and multiple sclerosis: its relation to the medial and lateral pain systems
Erik Scherder, Erik Wolters, Chris Polman, et al.
The Lancet. Neurology
|
August 28, 2003
Spinal-cord MRI in multiple sclerosis
Geert Lycklama, Alan Thompson, Massimo Filippi, et al.
Archives of Neurology
|
January 11, 2007
Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis
Lars Bö, Jeroen J G Geurts, Paul van der Valk, et al.
Lancet (London, England)
|
February 25, 2003
Interferons in relapsing remitting multiple sclerosis: a systematic review
Graziella Filippini, Luca Munari, Barbara Incorvaia, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 41) with videos related to
Sort By:
Page
of 5
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 26, 2004
The therapeutic value of cannabinoids in MS: real or imaginary?
Joep Killestein, Chris Polman
Lancet (London, England)
|
March 3, 2009
Improving function: a new treatment era for multiple sclerosis?
Alan Thompson, Chris Polman
Neurology
|
February 23, 2011
Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy
Reinhard Hohlfeld, Frederik Barkhof, Chris Polman
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
June 13, 2006
Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?
Chris Polman, Huub Schellekens, Joep Killestein
The Lancet. Neurology
|
December 29, 2004
Biological markers in CSF and blood for axonal degeneration in multiple sclerosis
Charlotte E Teunissen, Christine Dijkstra, Chris Polman
JAMA Neurology
|
November 7, 2012
Natalizumab: bench to bedside and beyond
Richard Rudick, Chris Polman, David Clifford, et al.
Neuroscience and Biobehavioral Reviews
|
September 7, 2005
Pain in Parkinson's disease and multiple sclerosis: its relation to the medial and lateral pain systems
Erik Scherder, Erik Wolters, Chris Polman, et al.
The Lancet. Neurology
|
August 28, 2003
Spinal-cord MRI in multiple sclerosis
Geert Lycklama, Alan Thompson, Massimo Filippi, et al.
Archives of Neurology
|
January 11, 2007
Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis
Lars Bö, Jeroen J G Geurts, Paul van der Valk, et al.
Lancet (London, England)
|
February 25, 2003
Interferons in relapsing remitting multiple sclerosis: a systematic review
Graziella Filippini, Luca Munari, Barbara Incorvaia, et al.
Page
of 5